Predictive factors for response to treatment in patients with advanced renal cell carcinoma

Abstract

Our findings highlight the usefulness of CAIX in selecting patients with advanced RCC as candidates for systemic treatment. PTEN and p21 may be important in predicting response to sunitinib. Thrombocytosis and neutrophilia correlate well with response to CK and NTD, respectively.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

“…The absence of statistical significance after multiple testing adjustment indicates potential weakness in the association. This finding is broadly consistent with the results from a similar study of 67 mRCC patients who had received antiangiogenic therapies [sunitinib ( n  = 61), including as first-line treatment ( n  = 60); sorafenib ( n  = 21); bevacizumab ( n  = 3); or temsirolimus ( n  = 19)]; for sunitinib-treated patients, lower HIF-1α expression was associated with statistically significantly longer PFS [11], possibly due to lesser angiogenesis pathway activation. While the statistical methodology of assessing HIF-1α expression was different compared with the current investigation, the overall results are consistent.…”

“…Finally, analyses of tumor samples from mRCC patients receiving sunitinib and other targeted agents via immunohistochemistry (IHC) and other methods have examined potential markers such as hypoxia-inducible factor 1-alpha (HIF-1α) [11–13]. …”

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

“…A screen of the titles and abstracts identified 50 papers eligible for the assessment of the prognostic value of CAIX status in patients with RCC. After carefully review of each of the 50 studies, certain studies were excluded for the following rationale: six studies evaluated CAIX status by enzyme-linked immunosorbent assay (ELISA) [23], [24], [25], [26], [27], [28]; five studies evaluated CAIX status by real-time-PCR [29], [30], [31], [32], [33]; one study was on the topic of a single nucleotide polymorphism in the CAIX gene [34]; fourteen studies did not report survival outcome on CAIX expression or survival outcome could not be extracted [17], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]; and nine studies contained overlapping data with other studies by the same authors or institutions [48], [49], [50], [51], [52], [53], [54], [55], [56]. Thus, fifteen papers were included in our meta-analysis to evaluate the relationship between CAIX expression and prognosis in patients with renal cell carcinoma [16], [18], [19], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68].…”

Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use

“…Several studies confirm these suppositions. CA IX was shown to be predictive of outcome of anti-VEGF and sunitinib therapy in metastatic CCRCC [133][134][135], and useful in selecting patients with advanced RCC as candidates for systemic therapy [136]. CA IX can predict doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification [137].…”